Indices of lipid peroxidation in vivo: Strengths and limitations

Free Radical Biology and Medicine

Volumn 28, Issue 12, 2000, Pages 1745-1750

  Meagher, Emma A ^a   Fitzgerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aldehydes; Eicosanoid; Free radical; Isoprostane; Lipids; Oxidant stress; Peroxidation

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE; ALKADIENE; ANTIOXIDANT; DNA; ETHANE; FREE RADICAL; GLUTATHIONE PEROXIDASE; ICOSANOID; ISOPROSTANE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTANE; POLYUNSATURATED FATTY ACID; PROTEIN; RNA; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

CLINICAL TRIAL; HUMAN; LIPID PEROXIDATION; MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 0034659145     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(00)00232-X     Document Type: Article

References (86)

1. Halliwell B. Free radicals and antioxidants. Nutr. Rev. 52:1994;253-265.
2. Seis H. Oxidative stress. 1985;Academic Press, London.
3. Brown M.S., Goldstein J.L. Receptor-mediated endocytosis insights from the lipoprotein receptor system . Proc. Natl. Acad. Sci. USA. 76:1979;3330-3337.
4. Steinberg D., Parthasarathy S., Carwe T.E., Khoo J.D., Witztum J.L. Beyond cholesterol modifications of low density lipoprotein that increase its atherogenicity . N. Engl. J. Med. 320:1989;915-924.
5. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet. 334:1994;793-795.
6. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1989;1372-1376.
7. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., Shih D.M., Van Lenten B.J., Frank J.S., Demer L. L; Edwards, P. A.; Fogelman, A. M. The yin and yang of oxidation in the development of the fatty streak a review based on the 1994 George Lyman Duff Memorial Lecture . Arterioscler. Thromb. Vasc. Biol. 16:1996;831-842.
8. Halliwell B. Oxidants and human disease some new concepts . FASEB J. 1:1987;358-364.
9. Thompson S., Smith M.T. Measurement of the diene conjugated form of linoleic acid in plasma by HPLC a questionable non-invasive assay of free radical activity? Chem. Biol. Interact. 55:1989;357-366.
10. Halliwell B., Gutteridge J.M.C. Lipid peroxidation, oxygen radicals, cell damage and antioxidant therapy. Lancet. 1:1984;1396-1397.
11. Haberland M.E., Fogelman A.M. The role of altered lipoproteins in the pathogenesis of atherosclerosis. Am. Heart J. 113:1987;573-577.
12. Brown M.S., Goldstein J.L. Lipoprotein metabolism in the macrophage implications for cholesterol deposition in atherosclerosis . Annu. Rev. Biochem. 52:1983;223-261.
13. Hoff H.F., O'Neill J., Chisolm G.M. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis. 9:1989;538-549.
14. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins a potential role in recruitment and retention of monocyte/macrophages during atherogenesis . Proc. Natl. Acad. Sci. USA. 84:1987;2995-2998.
15. Halliwell B., Chirico S. Lipid peroxidation its mechanism, measurement and significance . Am. J. Clin. Nutr. 57:(Suppl.):1993;715S-725S.
16. Esterbauer H.R., Schauer J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128.
17. Schauenstein E., Esterbauer H., Zollner H. Aldehydes in biological systems their natural occurrence and biological activities . 1977;Pion Ltd, London.
18. Esterbauer H. McBrien D.C.H., Slater T.F. Free radicals, lipid peroxidation and cancer. 1982;101-128 Academic Press, London.
19. Benedetti A., Comporti M., Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochem. Biophys. Acta. 620:1980;281-296.
20. Benedetti A., Casini A.F., Ferrali M., Comporti M. Effects of diffusible products of lipid peroxidation of rat liver microsomal lipids. Biochem. J. 180:1979;303-312.
21. Ferrali M., Fulceri R., Benedetti A., Comporti M. Effects of carbonyl (4-hydroxyalkenals) originating from peroxidation of liver microsomal lipids on various microsomal enzyme activities of liver. Res. Commun. Chem. Pathol. Pharmacol. 30:1980;99-112.
22. Schauenstein E. Effects of low concentrations of aldehydes on tumour cells and tumour growth. McBrien D.C.H., Slater T.F. Free radicals, lipid peroxidation and cancer. 1982;159-171 Academic Press, New York.
23. Cadenas E., Muller A., Brigelius R., Esterbauer H., Seis H. Effects of 4-hydroxynonenal by isolated hepatocytes. Biochem. J. 214:1983;479-487.
24. Haenen G.R., Tai Tin Tsoi J.N., Vermeulen N., Timmermann H., Bast A. Hydroxy-2,3-trans-nonenal stimulates microsomal lipid peroxidation by reducing the glutathione dependent protection. Arch. Biochem. Biophys. 259:1987;449-456.
25. Poot M., Verkerk A., Koster J.F., Esterbauer H., Jongkind J.F. Reversible inhibition of DNA and protein synthesis by cumene hydroperoxide and 4-hydroxynonenal. Mech. Ageing Dev. 43:1988;1-9.
26. Wawra E., Zollner H., Schaur R.J., Tillian H.M., Schauenstein E. The inhibitory effect of 4-hydroxynonenal on DNA-polymerases alpha and beta from rat liver and rapidly dividing Yoshida acites hepatoma. Cell Biochem. Funct. 4:1986;31-36.
27. Currico M. Interaction between neutrophil and 4-hydroxyalkenals and consequences on neutrophil motility. Free Radic. Res. Commun. 5:1988;55-66.
28. Cajone, F.; Salina, M.; Benelli-Tazzera, A. 4-Hydroxynonenal induces a DNA binding protein similar to the heat shock factor. Biochem. J. 262:900-979; 1989.
29. Van der Viet A., Bast A. Effect of oxidative stress on receptors and signal transmission. Chem. Biol. Interact. 85:1992;95-116.
30. Palinski W., Yla-Herttuala S., Rosenfeld M.E., Butler S.W., Socher S.A., Parthasarathy S., Curtiss L.K., Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis. 10:1990;325-335.
31. Blasig I.E., Grune T., Schonheit K., Rohde E., Jakstadt M., Haseloff R.F., Siems W.G. 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am. J. Physiol. 269:1995;H14-H22.
32. Ogihara T., Hirano K., Morinobu T., Kim H.S., Hiroi M., Ogihara T., Tamai H. Raised concentrations of aldehyde lipid peroxidation products in premature infants with chronic lung disease. Arch. Dis. Child. 80:1999;21F-25F.
33. Aleynik S.I., Leo M.A., Aleynik M.K., Lieber C.S. Increased circulating products of lipid peroxidation in patients with alcoholic liver disease. Alcohol Clin. Exp. Res. 22:1998;192-196.
34. Meagher E.A., Barry O.P., Burke A., Lucey M.R., Lawson J.A., Rokach J., FitzGerald G.A. Alcohol induced generation of lipid peroxidation products in humans. J. Clin Invest. 104:1999;805-813.
35. Holley A.E., Walker M.K., Cheeseman K.H., Salter T.F. Measurement of n-alkenals and hydroxyalkenals in biological samples. Free Radic. Biol. Med. 15:1993;281-289.
36. Frankel E.N. Recent advances in lipid oxidation. J. Sci. Food Agric. 54:1991;495-511.
37. Gutteridge J.M.C. Aspects to consider when detecting and measuring lipid peroxidation. Free Radic. Res. Commun. 1:1986;173-184.
38. Kosugi H., Kato T., Kikugawa K. Formation of yellow, orange and red pigments in the reaction of alk-2-enals with 2-thiobarbituric acid. Anal. Biochem. 165:1987;456-464.
39. Yeo H.C., Helbock H.J., Chyu D.W., Ames B.N. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal. Biochem. 220:1994;391-396.
40. Hamberg M., Svensson J., Samuelson B. Throboxanes a new group of biologically active compounds derived from prostaglandin endoperoxides . Proc. Natl. Acad. Sci. USA. 72:1975;2294-2298.
41. Corongiu F.P., Poli G., Dianzani M.U. Lipid peroxidation and molecular damage to polyunsaturated fatty acids in rat liver recognition of two classes of hydroperoxides formed under conditions in vivo . Chem. Biol. Interact. 59:1986;147-155.
42. Dormandy T.L., Wickens D.G. The experimental and clinical pathology of diene conjugation. Chem. Phys. Lipids. 45:1987;356-364.
43. Reily C.A., Cohen G., Lieverman M. Ethane evolution a new index of lipid peroxidation . Science. 183:1974;208-212.
44. Frank H., Hintze T., Bimboes D. Remmer, H. Monitoring lipid peroxidation by breath analysis endogenous hydrocarbons and their metabolic elimination . Toxicol. Appl. Pharmacol. 56:1980;337-344.
45. Kivits G.A.A., Ganguli-Swarttouw M.A.C.R., Christ E.J. The composition of alkanes in exhaled air of rats as a result of lipid peroxidation in vivo. Effects of dietary fatty acids, vitamin E and selenium. Biochem. Biophys. Acta. 665:1981;559-570.
46. Koster U., Albrecht D., Kapus H. Evidence for carbon tetrachloride and ethanol induced lipid peroxidation in vivo demonstrated by ethane production in mice and rats. Toxicol. Appl. Pharmacol. 41:1977;639-648.
47. Dresow B., Albert C., Zimmermann I., Nielson P. Ethane exhalation and vitamin E/ubiquinol status as markers of lipid peroxidation in ferrocene iron loaded rats. Hepatology. 21:1995;1099-1105.
48. Humad S., Zarling E., Clapper M., Skosey J.L. Breath pentane excretion as a marker of disease activity in rheumatoid arthritis. Free Radic. Res. Comm. 5:1988;101-106.
49. Weitz Z.W., Birnbaum A.J., Sobotka P.A., Zarling E.J., Skosey J.L. High breath pentane concentrations during acute myocardial infarction. Lancet. 337:1991;933-935.
50. Toshniwal P.K., Zarling E.J. Evidence for increase lipid peroxidation in multiple sclerosis. Neurochem. Res. 17:1992;205-207.
51. Drury J.A., Nycyk J.A., Cooke R.W.I. Pentane measurement in ventilated infants using a commercially available system. Free Radic. Biol. Med. 22:1997;895-900.
52. Springfield J.R., Levitt M.D. Pitfalls in the use of breath pentane measurements to assess lipid peroxidation. J. Lipid Res. 35:1994;1497-1504.
53. Mendis S., Sobotka P.A., Euler D.E. Pentane and isoprene in expired air from humans gas chromatographic analysis of single breath . Clin. Chem. 40:1994;1485-1488.
54. Allerheiligen S.R.B., Ludden T.M. The pharmacokinetics of pentane, a byproduct of lipid peroxidation. Drug Metab. Dispos. 15:1987;794-800.
55. Morita S., Snider M.T., Inada Y. Increased n-pentane excretion in humans a consequence of pulmonary oxygen exposure . Anesthesiology. 64:1986;730-733.
56. Reiter R., Burk R.F. Effect of oxygen tension on the generation of alkanes and malondialdehyde by peroxidizing rat liver microsomes. Biochem. Pharmacol. 36:1987;925-929.
57. Morrow J.D., Hill K.E., Burk R.F., Nammour T.M., Badr K.F., Roberts L.J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci USA. 87:1990;9383-9387.
58. Lawson J.A., Rokach J., FitzGerald G.A. Isoprostanes formation, analysis and use as indices of lipid peroxidation in vivo . J. Biol. Chem. 274:1999;24441-24444.
59. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest. 103:1999;422-427.
60. Harrison K., Murphy R.C. Isoleukotrienes biologically active free radical products of lipid peroxidation . J. Biol. Chem. 270:1995;17273-17278.
61. 2α is not modulated by thromboxane receptor isoforms. J. Biol. Chem. 271:1996;14916-14924.
62. 2α. J. Biol. Chem. 272:1997;27147-27154.
63. 2 isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA. 89:1992;10721-10725.
64. 2 receptors . J. Clin. Invest. 90:1992;136-141.
65. 2-isoprostane receptors on rat smooth muscle cells. Am. J. Physiol. 264:1993;C1619-C1624.
66. 2α-III, induce cardiomyocyte hypertrophy differential activation of downstream signaling pathways . J. Biol. Chem. 273:1998;22442-22452.
67. 2α, in rabbit lung in situ. Am. J. Physiol. 263(32):H660-H663; 1992.
68. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 270:1994;1192-1196.
69. 2 receptors . J. Clin. Invest. 90:1992;136-141.
70. 2α-III are mediated via thromboxane receptors in vivo. Circulation In press; 2000.
71. 2 isoprostanes are ligands for peroxisome proliferator-activated receptors α and γ (abstract). FASEB J. 13:1999;A1549.
72. 2α in human platelets. J. Biol. Chem. 270:1995;9800-9808.
73. 2α-I an index of lipid peroxidation in humans . Proc. Natl. Acad. Sci. USA. 95:1998;3449-3454.
74. 2 isoprostanes, 8,12-iso- and 5-epi-8,12-iso-isoprostane-VI, in human urine. J. Biol. Chem. 273:1998;29295-29301.
75. 2 isoprostanes by HPLC/tandem mass spectrometry. Proc. Natl. Acad. Sci. USA. 96:1999;13381-13386.
76. 2α. J. Biol. Chem. 274:1999;1313-1319.
77. 2α) by a stable isotope dilution mass spectrometric assay. Anal. Biochem. 269:1999;326-331.
78. 2α-III and an antioxidative product of γ-linolenic acid. J. Biol. Chem. 275:2000;2499-2504.
79. 2α excretion in man. J. Pharmacol. Exp. Ther. 275:1995;94-100.
80. 2α by human monocytes discriminate production by reactive oxygen species and PG G/H S-2 . J. Biol. Chem. 271:1996;8919-8924.
81. Reilly M., Delanty N., Lawson J.A., FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94:1996;19-25.
82. 2 isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100:1997;2028-2034.
83. 2α in acute coronary angioplasty Evidence for oxidant stress during coronary reperfusion in humans . Circulation. 96:1997;3314-3320.
84. Pratico D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. 4:1998;1189-1192.
85. Shaish A., George J., Gilburd B., Keren P., Levkovitz H., Haratas D. Dietary beta-carotene and a-tocopherol combination does not inhibit atherogenesis in an apoE-deficient mouse model. Atheroscler. Throm. Vasc. Biol. 19:1999;1470-1475.
86. Meagher E.A., Barry O.P., Bensinger S., Rokach J., FitzGerald G.A. Effects of chronic therapy with vitamin E on lipid peroxidation in vivo in healthy humans (abstract). J. Invest. Med. 46:1998;204A.